leisure time -WSS

leisure time

author：focus 2025-10-02 22:40:59 - browse：8752

Seng Cheng has been working in gene therapy for nearly as long as gene therapy has been a field. As a young scientist in the early 1990s, he was part of one of three teams racing to develop a gene therapy for cystic fibrosis, a high-profile effort that resulted in national headlines, prestigious publications, and zero patients cured.

So he’s seen the field’s highs and lows. Lately, there have been a lot of both, including at Pfizer, the company Cheng called home until this summer. The pharma brought three potentially powerful gene therapies for muscular dystrophy and hemophilia into late-stage trials but, in January, chose to abandon a large portfolio of early stage candidates that relied on the same technology: adeno-associated viruses, or AAVs, a group of small bugs that scientists spent two decades taming into a gene shipping system.

The move seemed emblematic. Across the industry, AAV companies have been struggling, either shelving programs or stopping work altogether, while investors shuttled money toward new technologies such as CRISPR and its various permutations. Longtime researchers feared promising drugs, particularly for ultra-rare diseases, might get lost in the shuffle.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Robert F. Kennedy is pitching centrism on health, even on abortion

WSS

'Revelatory' study finds a smoking impact that remains after quitting

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

Senators start work on Medicare physician payment reform

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

STAT Boddities: What happens to the brain when we get scared?

explore

leisure time

focus

New air purifier tech could be key to improving indoor air quality

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

United colonoscopy coverage change 'may cost lives,' doctors say

For Medicare Advantage, Democrats want stronger protections around AI

FDA approval of Sarepta Duchenne genetic therapy gives me hope

A disappointing year of Humira biosimilars

Medicare details structure of new drug price negotiation program

ACIP vaccine advisory panel sees its vacancies filled

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

The Readout: Gilead, Bernie Sanders, and other pharma news

focus

Readout Newsletter: Amylyx, Aurinia, and IQVIA

The Readout: Gilead, Bernie Sanders, and other pharma news

Congress might make insulin pumps more accessible to the blind

The Readout: Gilead, Bernie Sanders, and other pharma news

What we’ve learned from the Aduhelm mess

PhRMA lawsuit over Medicare drug price negotiation tossed

hotspot

hotspot

knowledge

leisure time